Validating Machine Learning-Designed Biased Agonism to Unlock Precision GPCR Therapeutics
10:00 am - Tuesday 2nd March 2027
- Demonstrating how Biagon’s machine learning platform integrates structural, experimental and computational data to predict GPCR signaling outcomes and guide the rational design of biased agonists
- Showcasing results in studies from obesity, pain and oncology programs demonstrating successful translation from computational prediction to experimental validation
- Exploring how predictive biased agonism can improve therapeutic selectivity and accelerate the development of next-generation GPCR-targeted medicines
